Thanks for clearing that up for me Fred. I'll be taking a position shortly.
RE: Watch list
Hi Teamwales. Quick reply... Reneuron will be manufacturing their own stem cells in just over one year. The cost of the dose will come right down. Volume manufacture of a successful drug will bring it down further. Reneuron is currently financed through to well into 2016 at which time successful phase 111 trials will attract big partners.Also three treatment lines will be well on the way to fruition. All in all a much safer gamble than we were at three years ago when the sp was much higher. Best wishes. Freddie
RE: Hi boba
Hi Chewise. Theres the UK stem cell summit next week and John Sinden is giving an update on Ren001. If I were a gambling man, not wishing to jump the gun, a few scans of before and after could tell an interesting story. In any event, in my book, his presentation is likely interest the media, investors and very likely provide an opportunity for the sp to rise. Hopefully he may also update the audience on his exosome research which is linked to that which has been seen in stem cell neural activity. Interviews with former patients could also be on the cards, as its happened before. All in all a good opportunity for advancement in sp Sorry for the scrappy reply but in a rush. Best wishes. Freddie
Been observing this share for quite some time. Looking to get involved however I do have some doubts regarding finances. Obviously from the PISCES trail things are looking good, but the cost for each patient to receive stem cell treatment is quite high. Is this financial viable, and would clients be willing to pay to have this?
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.